It’s the other job that in recent months has been the topic of fervid conversation, disdain and intrigue among any number of groups—pharmaceutical companies, short sellers, meme-stock investors, MAHA (“Make America Healthy Again”) leaders and, of course, those trying to find an affordable way to shed a few pounds. Dudum launched Hims in 2017 as an Instagram-inspired telehealth startup that would fill a void in the fragmented US health-care system, enabling customers to buy drugs on a subscription basis almost as easily as they could purchase razor blades from Dollar Shave Club. Today, Hims is a public company that last year had 2.2 million subscribers, $1.5 billion in annual revenue and, in mid-July, a market value of almost $11 billion.